Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803853 | 0.94 | TP53 (0.40) | ALDH1A1SMN1; SMN2TPSAB1LMNATP53 | |
| SCHEMBL23519429 | 0.90 | TP53 (0.37) | ALDH1A1SMN1; SMN2LMNATP53 | |
| SCHEMBL29603305 | 0.89 | TP53 (0.37) | ALDH1A1SMN1; SMN2LMNATP53 | |
| SCHEMBL15326722 | 0.89 | TP53 (0.42) | ALDH1A1SMN1; SMN2TPSAB1LMNATP53 | |
| SCHEMBL29742315 | 0.82 | TP53 (0.43) | ALDH1A1SMN1; SMN2TPSAB1LMNATP53 | |
| SCHEMBL21300882 | 0.81 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2TPSAB1LMNATP53 | |
| SCHEMBL23031865 | 0.81 | KDM4E (0.36) | SMN1; SMN2TP53MEN1KMT2AMAPT | |
| SCHEMBL1299177 | 0.78 | GAA (0.53) | SMN1; SMN2TPSAB1LMNAGAAPRSS1 | |
| SCHEMBL16974355 | 0.78 | TP53 (0.40) | ALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL29408822 | 0.78 | LMNA (0.58) | ALDH1A1SMN1; SMN2LMNATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | claimed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | claimed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | claimed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | claimed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025129332-A1 | METHOD OF PROGNOSIS AND MONITORING OF CANCER PATIENT AND OF DETERMINING IMMUNOLOGICAL STATUS OF A SUBJECT | 11949098 CANADA INC. (NUREDCO) C/O JEAN I. TCHERVENKOV (CA) | 2025-06-26 | — | — | WO | disclosed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | disclosed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | disclosed |
| US-20140295460-A1 | Analyte Detection Using Magnetic Hall Effect | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140178901-A1 | Molecular Analysis of Tumor Samples | THE GENERAL HOSPITAL CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013187954-A1 | MAGNETIC LABELING OF BACTERIA | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION | 2013-11-14 | — | — | US | disclosed |
| WO-2011112970-A2 | COMPOSITIONS AND METHODS FOR BIOCONJUGATION TO QUANTUM DOTS | THE GENERAL HOSPITAL CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ALDH1A1 2270/4885SMN1; SMN2 657/4885TPSAB1 4600/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ALDH1A1 2270/4885SMN1; SMN2 657/4885TPSAB1 4600/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | ALDH1A1 2270/4885SMN1; SMN2 657/4885TPSAB1 4600/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | ALDH1A1 2270/4885SMN1; SMN2 657/4885TPSAB1 4600/4885 |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | ALDH1A1 368/4885SMN1; SMN2 1732/4885TPSAB1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.